CVS Health Corporation's results for Q3 2026 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-04. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $108,399 million (+5.4% vs a year earlier) |
| Diluted EPS (GAAP) | $1.68 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $2.09 |
| Full-year guidance | Raised |
Guidance
CVS raised FY2026 guidance: GAAP EPS at least $6.98, adjusted EPS at least $8.20, operating cash flow at least $15.5 billion.
Why this label: 'Raising full-year 2026 guidance': GAAP EPS to at least $6.98 from $6.84-7.04, adjusted EPS to at least $8.20 from $7.90-8.10; nothing core lower.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| GAAP diluted EPS | FY2026 | at least $6.98 | $6.84–7.04 |
| adjusted EPS | FY2026 | at least $8.20 | $7.90–8.10 |
| cash flow from operations | FY2026 | at least $15.5 billion | at least $11.5 billion |
| total revenues | FY2026 | at least $420.0 billion | not stated |
From the release
Revenue: "Total revenues · 108,399 · 102,871"
Earnings per share: "Third quarter GAAP diluted EPS of $1.68 and Adjusted EPS of $2.09"
GAAP diluted EPS: "GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04"
adjusted EPS: "Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10"
cash flow from operations: "Cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 adjusted EPS guidance to at least $8.20 from $7.90–$8.10.
Source
CVS Health Corporation earnings release (SEC filing), accession 0000064803-26-000107, filed 2026-11-04.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.